Shire

AspireHR Completes Phase 1 SAP HR Initiative for Shire Pharmaceuticals

AspireHR and Shire Pharmaceuticals complete Phase 1 of their shared SAP human resources initiative. Wayne, PA (PRWEB) August 7, 2009 -- AspireHR, an SAP HR software, consulting, and SaaS company, is proud to announce the successful Go-Live of Phase 1 of their SAP HR ini...

GlaxoSmithKline and Shire Enter Agreement to Co-Promote Vyvanse(R) (lisdexamfetamine dimesylate) CII for Adult Attention Deficit Hyperactivity Disorder

RESEARCH TRIANGLE PARK, N.C., March 31 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc (NYSE: GSK ) has entered into a co-promotion agreement with Shire plc (LSE: SHP, Nasdaq: SHPGY ) for Vy v a n s e(R) , to help improve the recognition and treatment of adult Attention Deficit Hyperactivi...

VIDEO from Medialink and Shire plc: Rare Diseases Must Be Top of the Health Agenda

First European Rare Disease Day highlights impact on people affected by rare diseases NEW YORK, Feb. 28 /PRNewswire/ -- European Rare Disease Day -- The first ever European Rare Disease Day will be launched on Friday 29 February...because it's a rare day that only c...

The Lachlan Shire Council To Fund GP For Condobolin Health Service

The Lachlan Shire Council decides to pay for the services of another doctor at the Condobolin Aboriginal Health Service. // The council have decided to give the Condobolin Aboriginal Health Service $150,000 so as to pay a doctor to work as a general practitioner and be a second visiting medic...

More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals

Drugs meant for treatment of Attention Deficit Hyperactivity Disorder (ADHD), Ritalin (Novartis AG) and Adderall (Shire Pharmaceuticals) would be subjected to stringent clinical trials to assess the safety and side effects // of the drug. The decision has been taken following the reports of t...

VYVANSE CII provided significant efficacy at 14 hours in adults with ADHD

... Hollywood, FL July 1, 2009 shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical compa...over 12 percent based on weekly branded prescription volume. Additionally, shire has executed agreements with 10 of Shire's top 11 managed care organization...

Global Autoimmune Disease Therapeutics Market to Reach $50 Billion by 2015, According to a New Report by Global Industry Analysts

...e AG, Genentech, Inc., GlaxoSmithKline plc, Johnson & Johnson, Inc., Merck Serono SA, Novartis AG, sanofi-aventis SA, Schering-Plough Corporation, shire Pharmaceuticals Group plc., Teva Pharmaceuticals Industries Limited, UCB Pharma. "Autoimmune Disease Therapeutics: A Global Strategic Busine...

Shire's INTUNIV (Guanfacine) extended release in children with ADHD and oppositional symptoms

... San Francisco, CA May 18, 2009 shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical compa...UNIV for treating ADHD in this patient population." On January 26, 2009, shire filed a resubmission to the US Food and Drug Administration (FDA) of the Ne...

Shire Expands Gastrointestinal Patient Assistance Program for Uninsured or Unemployed Americans

... Free Medication Provided by shire to Patients Taking Lialda(R) (mesalamine) or Penta... PHILADELPHIA, May 18 /PRNewswire-FirstCall/ -- shire plc (LSE: SHP, Nasdaq: SHPGY ), the global speci... prescribed gastrointestinal (GI) medications from shire by expanding its Patient Assistant Program (PAP). ...

Shire to Present New Scientific Data on its ADHD Treatments at a National Scientific Meeting of Psychiatrists on May 18

... PHILADELPHIA, May 15 /PRNewswire-FirstCall/ -- shire plc (LSE: SHP, Nasdaq: SHPGY ), the global speci...or behavioral modification, and medication. shire PLC Shire's strategic goal is to become the ... on meeting the needs of the specialist physician. shire focuses its business on attention deficit hyperact...

More>>

Shire in Medical Technology

Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA

... Massachusetts, August 3 /PRNewswire-FirstCall/ -- shire plc (LSE: SHP, NASDAQ: SHPGY ), the global speci...treatment protocol for velaglucerase alfa and that shire has begun its rolling submission of the New Drug A...y perspective," said Sylvie Gregoire, President of shire Human Genetic Therapies. "This data are consistent...

FDA Issues Complete Response Letter for INTUNIV(TM) (guanfacine) Extended Release for the Treatment of ADHD in Children and Adolescents

... PHILADELPHIA, July 28 /PRNewswire-FirstCall/ -- shire plc (LSE: SHP, NASDAQ: SHPGY ), the global speci...e Response letter or request new clinical studies. shire and the FDA will continue to work together to reso... quarter as planned," said Mike Cola, President of shire Specialty Pharmaceuticals. "When approved, INTUNIV...

Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease

..., Massachusetts, July 16 /PRNewswire-FirstCall/ -- shire plc (LSE: SHP, NASDAQ: SHPGY ), the global speci...pment for the treatment of Type I Gaucher disease. shire is working with the FDA to determine subsequent st...ons are completed and submitted for review. shire is completing a phase III clinical program that in...

Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease

...N, Massachusetts, July 6 /PRNewswire-FirstCall/ -- shire plc (LSE: SHP, NASDAQ: SHPGY ), the global speci... and carries a human glycosylation pattern. shire has sufficient supply of velaglucerase alfa to meet anticipated patient demand. shire is working with the FDA to file a New Drug Applica...

Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease

...ration Trial Update Amicus and its partner, shire Human Genetic Therapies, Inc. (Shire HGT), have co...ps using descriptive statistics. Amicus and shire HGT are reviewing the final EMEA feedback and will...an medicinal product in the European Union. shire HGT Collaboration In November 2007, Amicus e...

Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week

... CHICAGO, June 1 /PRNewswire-FirstCall/ -- shire plc (LSE: SHP, Nasdaq: SHPGY ), the global speci...hew Cabrey (Shire) +1 484 595 8248 shire PLC Shire's strategic goal is to become the lea... on meeting the needs of the specialist physician. shire focuses its business on attention deficit hyperact...

New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI)

... PHILADELPHIA, May 22 /PRNewswire-FirstCall/ -- shire plc (LSE: SHP, Nasdaq: SHPGY ), the global speci...or behavioral modification, and medication. shire PLC Shire's strategic goal is to become the ... on meeting the needs of the specialist physician. shire focuses its business on attention deficit hyperact...

Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms

... SAN FRANCISCO, May 18 /PRNewswire-FirstCall/ -- shire plc (LSE: SHP, Nasdaq: SHPGY ), the global speci...his patient population." On January 26, 2009, shire filed a resubmission to the US Food and Drug Admin... or behavioral modification, and medication. shire PLC Shire's strategic goal is to become the lea...

Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent

... Plicera as part of a strategic collaboration with shire Human Genetic Therapies (HGT), a business unit of shire plc, to develop and commercialize Amicus' three le...osomal storage disorders. Under the collaboration, shire received commercial rights outside of the United S...

Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)

... DUBLIN, March 16 /PRNewswire-FirstCall/ -- shire plc (LSE: SHP, NASDAQ: SHPGY ), the global speci... since 2006. EQUASYM IR and XL will provide shire with an entry to the European ADHD market upon com...lands, Norway, Sweden, UK, Mexico and South Korea. shire will be working to progress a number of additional...

Shire in Biological News

Court Approves Scheme of Arrangement

...IA, Pennsylvania, May 22 /PRNewswire-FirstCall/ -- shire plc (LSE: SHP)(NASDAQ: SHPGY ), the global specia...h Court approved the scheme of arrangement between shire plc and its ordinary shareholders at a hearing tod...008, results in the UK listed, Jersey incorporated shire Limited (LSE: SHP, NASDAQ: SHPGY) becoming the new...

Shire in Biological Technology

The Crohn's & Colitis Foundation of America and Shire Launch Virtual 'IBD March on the Hill' to Increase Funding for Digestive Disease Research

Virtual March Connects 'IBD Day on the Hill' Advocates in Washington, D.C. with Online Supporters PHILADELPHIA, May 6 /PRNewswire-FirstCall/ -- Today the Crohn's & Colitis Foundation of America (CCFA) and Shire plc (LSE: SHP, Nasdaq: SHPGY ) joined forces to launch the first-ever virt...

Publication of Shire plc's Annual Report 2008

DUBLIN, March 25 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY ), the global specialty biopharmaceutical company, announces that its Annual Report and Accounts in respect of the year ended December 31, 2008 has been published on its website. Shire has previously announced unau...

Change of Name to Shire plc

DUBLIN, Ireland, October 1 /PRNewswire-FirstCall/ -- Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that following the approval by shareholders at the Annual General Meeting on September 24, 2008, the Company has changed its name to Shire plc...

Application for Listing of Shire Limited Ordinary Shares

BASINGSTOKE, England and PHILADELPHIA, Pennsylvania, May 23 /PRNewswire-FirstCall/ -- Shire Limited ("Shire") (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that an application has been made to the UK Listing Authority and to the London Stock Exchange for ...

Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance

BASINGSTOKE, England and PHILADELPHIA, April 25 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company announces results for the three months to March 31, 2008. Q1 2008 Financial Highlights - Product sales up 37% to $632m - New produ...

New Shire Holding Company Proposal

BASINGSTOKE, England and PHILADELPHIA, April 16 /PRNewswire-FirstCall/ -- Shire plc ("Shire" or the "Company") (LSE: SHP) (NASDAQ: SHPGY ), the global specialty biopharmaceutical company, announces that further to yesterday's announcement regarding Shire's new holding company proposal, it wil...

Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001

BALTIMORE, Dec. 14 /PRNewswire/ -- Alba Therapeutics Corporation announced today that it has entered into a strategic collaboration with Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ), to jointly develop AT-1001, Alba's lead inhibitor of barrier dysfunction in various gastrointestinal ("GI") di...

Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007

BASINGSTOKE, England, Oct. 17 /PRNewswire-FirstCall/ -- Below is updated text of Shire plc's conference call notification. Please note U.S. release times and conference call times have been updated from an earlier release. Shire PLC (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ) the global specialty bio...

Graham Hetherington Appointed Chief Financial Officer and Board Director at Shire

BASINGSTOKE, England, June 10 /PRNewswire-FirstCall/ -- The Board of Directors of Shire Limited (LSE: SHP)(NASDAQ: SHPGY ), the global specialty biopharmaceutical company, announces today that Graham Hetherington will join the Company as Chief Financial Officer and Executive Board Director on...

Dr Michael Rosenblatt Appointed Non-Executive Director at Shire

BASINGSTOKE, England, April 24 /PRNewswire-FirstCall/ -- The Board of Directors of Shire plc (LSE: SHP) (NASDAQ: SHPGY ), the global specialty biopharmaceutical company, announces today that Michael Rosenblatt M.D. will join the Board as a Non-Executive Director with immediate effect. Dr Ro...